Biotech Growth Trust plc (The) (BIOG) Ordinary 25p
No change
- Add to watchlist
- Create an alert
- This stock can be held in a
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
n/a
n/a
1,068.00p
798.42
726.00p
n/a
616.00p
-10.57%
12.00p (1.68%) Previous:
12.00p
n/a
n/a
GBX
Price
-
Net Asset Value (NAV)
Performance
| 1 week 1W | 3.2% | 1 year 1Y | 26.96% |
|---|---|---|---|
| 1 month 1M | 3.13% | 2 years 2Y | 10.7% |
| 3 months 3M | 7.28% | 3 years 3Y | 11.46% |
| 6 months 6M | 16.17% | 5 years 5Y | 42.65% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Trust Basics
| Benchmark: | NASDAQ Biotechnology TR GBP |
|---|---|
| Annual management charge: | n/a |
| Performance fee: | Yes |
| Ongoing charge: | 1.20% |
| Dividend yield: | n/a |
| Dividend frequency: | None |
| Total assets: | £220m |
| Gross gearing: | 5% |
| Market capitalisation:Market cap.: | £186m |
| Shares in issue: | 26.07 million |
| Legal structure | Closed Ended Investment Company |
| Domicile: | United Kingdom |
| ISIN | GB0000385517 |
Dividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
Objective
NET ASSET VALUE (NAV)
| Estimated NAV: | 798.42p |
|---|---|
| Latest actual NAV: | 796.16p |
| Latest actual NAV date: | 23 June 2025 |
| Premium/Discount: | -10.57% |
| 12m average Premium/Discount: | -8.51% |
| NAV frequency: | Daily |
| Security | Weight |
|---|---|
| Gilead Sciences Inc | 12.69% |
| Sarepta Therapeutics Inc | 6.04% |
| Neurocrine Biosciences Inc | 4.97% |
| Argen X SE EUR0.10 | 4.89% |
| Amgen Inc | 4.18% |
| Avidity Biosciences Inc Ordinary Shares | 3.85% |
| Xenon Pharmaceuticals Inc | 3.63% |
| Cytokinetics Inc | 3.46% |
| Amicus Therapeutics Inc | 3.35% |
| Alnylam Pharmaceuticals Inc | 3.32% |
| Sector | Weight |
|---|---|
| Healthcare | 98.62% |
| Country | Weight |
|---|---|
| United States | 88.76% |
| Canada | 4.60% |
| China | 4.39% |
| Switzerland | 1.15% |
| Germany | 0.97% |
Key Dates
| Launch date: | 23 June 1997 |
|---|---|
| Financial year end: | March |
| Next AGM: | July 2025 |
What is a Value Assessment?
Fund Managers are required to regularly assess whether the fund they manage delivers value to investors. When completing their assessment, they will consider investment performance, service offered, costs and charges, and competitor funds. The Assessment of Value for funds is subject to the Financial Conduct Authority's Collective Investment Scheme (COLL) rules or a Price and Value Assessment (PRIN) for other funds not subject to COLL rules.
Why it matters to investors?
The Value Assessment helps an investor understand how a Fund Manager has considered how their fund has delivered value for money or is expected to deliver value for money. The Fund Manager will explain the actions they are taking if their fund has not delivered value for money or it is not expected to deliver value for money.
Value Assessment
| Value Assessment review date: | 31 March 2024 |
|---|---|
| Value Assessment next review date: | 31 March 2025 |
| Is Assessment of Value required under COLL: | No |
| Outcome of COLL Assessment of Value: | n/a |
| Outcome of PRIN Value Assessment or review: | Product expected to provide fair value for reasonably foreseeable period |
| Other review related to value and or charges: | - |
| Further information: | - |
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.